N/A
N=123
Relation Between NLR and IMR in STEMI Patients
Myocardial Infarction · Death
Bottom Line
View on ClinicalTrials.gov: NCT02828137 ↗Enrolled (actual)
123
Serious AEs
—
Results posted
Aug 2016
Primary outcome: Primary: Index of Microcirculatory Resistance — 21.94; 23.22; 32.95 IMR
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 30+ yrs
- Sex
- All
- Sponsor
- Inha University Hospital
- Primary completion
- Oct 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Index of Microcirculatory Resistance |
21.94; 23.22; 32.95 | — |
Summary
The neutrophil-to-lymphocyte ratio (NLR) has been proven to be reliable inflammatory marker for atherosclerotic process and predictor for clinical outcomes in patients with various cardiovascular diseases. Recent study reported elevated NLR was associated with impaired myocardial perfusion in ST-segment elevation myocardial infarction (STEMI) patients. The investigators sought to determine whether NLR is associated with coronary microcirculation assessed by index of microcirculatory resistance (IMR) in STEMI patients who undergone primary percutaneous coronary intervention (PCI). A total of 123 patients with STEMI underwent successful primary PCI were consecutively enrolled. NLR at admission was calculated, and the patients were divided into three groups according to NLR tertiles. IMR was measured by intracoronary thermodilution-derived method immediately after index PCI.
Eligibility Criteria
Inclusion Criteria
- STEMI patients who undergone primary PCI
Exclusion Criteria
- unprotected left main coronary artery disease
- stent thrombosis presentation
- a history of coronary artery bypass graft surgery
- prior intravenous thrombolytic therapy before PCI
- high degree atrioventricular block
- remained cardiogenic shock after complete PCI
- contraindication for use of adenosine
- post-PCI thrombolysis in myocardial infarction (TIMI) flow grade 0 or 1
Data sourced from ClinicalTrials.gov (NCT02828137). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.